Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab

Leuk Lymphoma. 2008 Sep;49(9):1817-20. doi: 10.1080/10428190802163289.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal / toxicity
  • Antibodies, Monoclonal, Murine-Derived
  • Female
  • Humans
  • Leukemia, Hairy Cell / drug therapy*
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab